TY - JOUR
T1 - The prevalence, predictors and outcomes of acute liver injury among patients with COVID-19
T2 - A systematic review and meta-analysis
AU - Harapan, Harapan
AU - Fajar, Jonny Karunia
AU - Supriono, Supriono
AU - Soegiarto, Gatot
AU - Wulandari, Laksmi
AU - Seratin, Fiha
AU - Prayudi, Nyoman Gede
AU - Dewi, Dara Puspita
AU - Monica Elsina, Maria Theresia
AU - Atamou, Lasarus
AU - Wiranata, Sinta
AU - Aprianto, Dhito Pemi
AU - Friska, Erlin
AU - Sari Firdaus, D. Fitria
AU - Alaidin, Makdum
AU - Wardhani, Firdha Aprillia
AU - Husnah, Milda
AU - Hidayati, Nurdina Wahyu
AU - Hendriyanti, Yeni
AU - Wardani, Kristia
AU - Evatta, Arde
AU - Manugan, Reizal Audi
AU - Pradipto, Wiryawan
AU - Rahmawati, Ade
AU - Tamara, Fredo
AU - Mahendra, Aditya Indra
AU - Nainu, Firzan
AU - Santoso, Budi
AU - Irawan Primasatya, Chandra Adi
AU - Tjionganata, Nindy
AU - Budiman, Hendarto Arif
N1 - Funding Information:
Authors would like to thank to Lembaga Pengelola Dana Pendidikan (LPDP) Republic of Indonesia for supporting our project. Harapan is supported by the Indonesian Endowment Fund for Education and the Indonesian Science Fund through the International Collaboration RISPRO Funding Program (No. RISPRO/KI/B1/TKL/5/15448/1/2020) and Universitas Syiah Kuala (Ministry of Education, Culture, Research and Technology) through the H‐Index Research Scheme (No. 169/UN11/SPK/PNBP/2021).
Funding Information:
Authors would like to thank to Lembaga Pengelola Dana Pendidikan (LPDP) Republic of Indonesia for supporting our project. Harapan is supported by the Indonesian Endowment Fund for Education and the Indonesian Science Fund through the International Collaboration RISPRO Funding Program (No. RISPRO/KI/B1/TKL/5/15448/1/2020) and Universitas Syiah Kuala (Ministry of Education, Culture, Research and Technology) through the H-Index Research Scheme (No. 169/UN11/SPK/PNBP/2021).
Publisher Copyright:
© 2021 John Wiley & Sons Ltd.
PY - 2022/5
Y1 - 2022/5
N2 - The data on the predictors and prognosis of acute liver injury (ALI) among patients in coronavirus disease 2019 (COVID-19) patients are limited. The aim of this study was to determine the prevalence, predictors and outcomes of ALI among patients with COVID-19. A systematic review was conducted up to 10 June 2021. The relevant papers were searched from PubMed, Embase, Cochrane and Web of Science, and the data were analysed using a Z test. A total of 1331 papers were identified and 16 papers consisting of 1254 COVID-19 with ALI and 4999 COVID-19 without ALI were analysed. The cumulative prevalence of ALI among patients with COVID-19 was 22.8%. Male and having low lymphocyte levels were more likely to be associated with ALI compared with female and having higher lymphocyte level, odds ratio (OR): 2.70; 95% confidence interval (CI): 2.03, 3.60 and mean difference (MD) −125; 95% CI: −207, −43, respectively. COVID-19 patients with ALI had higher risk of developing severe COVID-19 compared with those without ALI (OR: 3.61; 95% CI: 2.60, 5.02). Our findings may serve as the additional evaluation for the management of ALI in COVID-19 patients.
AB - The data on the predictors and prognosis of acute liver injury (ALI) among patients in coronavirus disease 2019 (COVID-19) patients are limited. The aim of this study was to determine the prevalence, predictors and outcomes of ALI among patients with COVID-19. A systematic review was conducted up to 10 June 2021. The relevant papers were searched from PubMed, Embase, Cochrane and Web of Science, and the data were analysed using a Z test. A total of 1331 papers were identified and 16 papers consisting of 1254 COVID-19 with ALI and 4999 COVID-19 without ALI were analysed. The cumulative prevalence of ALI among patients with COVID-19 was 22.8%. Male and having low lymphocyte levels were more likely to be associated with ALI compared with female and having higher lymphocyte level, odds ratio (OR): 2.70; 95% confidence interval (CI): 2.03, 3.60 and mean difference (MD) −125; 95% CI: −207, −43, respectively. COVID-19 patients with ALI had higher risk of developing severe COVID-19 compared with those without ALI (OR: 3.61; 95% CI: 2.60, 5.02). Our findings may serve as the additional evaluation for the management of ALI in COVID-19 patients.
KW - COVID-19
KW - acute liver injury
KW - outcome
KW - predictor
KW - prevalence
UR - http://www.scopus.com/inward/record.url?scp=85116888408&partnerID=8YFLogxK
U2 - 10.1002/rmv.2304
DO - 10.1002/rmv.2304
M3 - Review article
AN - SCOPUS:85116888408
SN - 1052-9276
VL - 32
JO - Reviews in Medical Virology
JF - Reviews in Medical Virology
IS - 3
M1 - e2304
ER -
